Nippon Shinyaku Co
Nippon Shinyaku Co., Ltd., commonly referred to as Nippon Shinyaku, is a prominent pharmaceutical company headquartered in Japan. Established in 1923, the company has made significant strides in the healthcare sector, focusing on the development and manufacturing of innovative pharmaceuticals and medical devices. With a strong presence in both domestic and international markets, Nippon Shinyaku operates extensively across Asia, Europe, and North America. The company is renowned for its core products, which include prescription medications, particularly in the fields of oncology, urology, and orthopaedics. Nippon Shinyaku's commitment to research and development has positioned it as a leader in the pharmaceutical industry, with notable achievements in drug discovery and a robust pipeline of new therapies. Through its dedication to improving patient outcomes, Nippon Shinyaku continues to enhance its market position as a trusted provider of high-quality healthcare solutions.
DitchCarbon Score
How does Nippon Shinyaku Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nippon Shinyaku Co's score of 23 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Nippon Shinyaku Co's reported carbon emissions
In 2023, Nippon Shinyaku Co., based in Japan, reported total greenhouse gas emissions of approximately 4366000 kg CO2e for Scope 1 and 4057000 kg CO2e for Scope 2, with significant Scope 3 emissions amounting to about 188834000 kg CO2e. This reflects a commitment to transparency in their carbon footprint across all scopes of emissions. Nippon Shinyaku has set ambitious climate targets, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030, using FY2020 as the baseline. Additionally, they plan to cut Scope 3 emissions from purchased goods and services by 25% within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to global efforts to limit warming to 1.5°C. The company's emissions data shows a trend of increasing emissions from 2013 to 2022, with a peak in 2018 at approximately 9181000 kg CO2e for Scope 1. However, their commitment to significant reductions indicates a proactive approach to addressing climate change and improving sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 428,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | 00,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nippon Shinyaku Co is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
